MDM4 (MDMX) and its transcript variants

Current Genomics

Volumn 10, Issue 1, 2009, Pages 42-50

  Mancini, Francesca ^a,b   Di Conza, G ^a,c   Moretti, F ^a  

^a CNR   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

MDM2; MDM4; MDM4 211; MDM4 S; p53; Transcript variants

Indexed keywords

CASEIN KINASE IALPHA; CELL PROTEIN; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KARYOPHERIN ALPHA; MESSENGER RNA; PEPTIDASE; PROTEIN 14 3 3; PROTEIN MDM2; PROTEIN MDM4 211; PROTEIN MDM4 A; PROTEIN MDM4 G; PROTEIN MDM4 S; PROTEIN MDM4 XALT1; PROTEIN MDM4 XALT2; PROTEIN MDMX; PROTEIN P21; PROTEIN P300; PROTEIN P53; PROTEIN S II; RETINOBLASTOMA PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR E2F1; UBIQUITIN SPECIFIC PEPTIDASE 7; UNCLASSIFIED DRUG;

CARCINOGENESIS; CHROMOSOME 1Q; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE HOMOLOGY; SOLID TUMOR;

EID: 65949093491     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920209787581280     Document Type: Review

References (73)

1. Shvarts, A., Steegenga, W.T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R.C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A.J., Jochemsen, A.G. MDMX:a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996, 1: 5349-57.
2. Shvarts, A., Bazuine, M., Dekker, P., Ramos, Y.F., Steegenga, W.T., Merckx, G., van Ham, R.C., van der Houven van Oordt, W., van der Eb, A.J., Jochemsen, A.G. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics 1997, 1: 34-42.
3. McCoy, M.A., Gesell, J.J., Senior, M.M., Wyss, D.F. Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation. Proc. Natl. Acad. Sci. USA 2003, 100: 1645-1648.
4. Freedman, D.A., Epstein, C.B., Roth, J.C., Levine, A.J. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med. 1997, 3: 248-59.
5. Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., Helin, K., Pelicci, P.G., Jochemsen, A.G., Marine, J.C. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol. 2004, 24: 5835-43.
6. Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y.F., van der Eb, A.J., Jochemsen, A.G., Lane, D.P. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 1999, 18: 189-99.
7. Popowicz, G., Czarna, A., Holak, T. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008, 7: 2441-3.
8. Popowicz, G.M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., Holak, T.A. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 2007, 6: 2386-92.
9. Macchiarulo, A., Giacchè, N., Carotti, A., Baroni, M., Cruciani, G., Pellicciari, R. Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition. J. Chem. Inf. Model 2008, 48: 1999-2009.
10. Laurie, N.A., Donovan, S.L., Shih, C.S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., Johnson, D., Wilson, M., Rodriguez-Galindo, C., Quarto, M., Francoz, S., Mendrysa, S.M., Guy, R.K., Marine, J.C., Jochemsen, A.G., Dyer, M.A. Inactivation of the p53 pathway in retinoblastoma. Nature 2006, 444: 61-6.
11. Hu, B., Gilkes, D.M., Farooqi, B., Sebti, S.M., Chen, J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J. Biol. Chem. 2006, 281: 33030-5.
12. Patton, J.T., Mayo, L.D., Singhi, A.D., Gudkov, A.V., Stark, G.R., Jackson, M.W. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006, 66: 3169-76.
13. Wade, M., Wong, E.T., Tang, M., Stommel, J.M., Wahl, G.M. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 2006, 281: 33036-44.
14. Fang, S., Jensen, J.P., Ludwig, R.L., Vousden, K.H., Weissman, A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 2000, 275: 8945-51.
15. Honda, R., Yasuda, H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000, 19: 1473-6.
16. Marine, J.C., Jochemsen, A.G. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 2005, 331: 750-60.
17. Linares, L.K., Hengstermann, A., Ciechanover, A., Müller, S., Scheffner, M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl. Acad. Sci. USA 2003, 100: 12009-14.
18. Kostic, M., Matt, T., Martinez-Yamout, M.A., Dyson, H.J., Wright, P.E. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J. Mol. Biol. 2006, 363: 433-50.
19. Poyurovsky, M.V., Priest, C., Kentsis, A., Borden, K.L., Pan, Z.Q., Pavletich, N., Prives, C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2007, 26: 90-101.
20. Uldrijan, S., Pannekoek, W.J., Vousden, K.H. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 2007, 26: 102-12.
21. Singh, R.K., Iyappan, S., Scheffner, M. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2. J. Biol. Chem. 2007, 282: 10901-7.
22. Sharp, D.A., Kratowicz, S.A., Sank, M.J., George, D.L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 1999, 274: 38189-96.
23. Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., Ohtsubo, M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 1999, 447: 5-9.
24. Kawai, H., Lopez-Pajares, V., Kim, M.M., Wiederschain, D., Yuan, Z.M. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res. 2007, 67: 6026-30.
25. Linke, K., Mace, P.D., Smith, C.A., Vaux, D.L., Silke, J., Day, C.L. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 2008, 15: 841-8.
26. LeBron, C., Chen, L., Gilkes, D.M., Chen, J. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 2006, 25: 1196-206.
27. Wang, B., Alam, S.L., Meyer, H.H., Payne, M., Stemmler, T.L., Davis, D.R., Sundquist, W.I. Structure and ubiquitin interactions of the conserved zinc finger domain of Npl4. J. Biol. Chem. 2003, 278: 20225-34.
28. Alam, S.L., Sun, J., Payne, M., Welch, B.D., Blake, B.K., Davis, D.R., Meyer, H.H., Emr, S.D., Sundquist, W.I. Ubiquitin interactions of NZF zinc fingers. EMBO J. 2004, 23: 1411-21.
29. Gentiletti, F., Mancini, F., D'Angelo, M., Sacchi, A., Pontecorvi, A., Jochemsen, A.G., Moretti, F. MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. Oncogene 2002, 21: 867-77.
30. Pan, Y., Chen, J. Modification of MDMX by sumoylation. Biochem. Biophys. Res. Commun. 2005, 332: 702-9.
31. Elias, B., Laine, A., Ronai, Z. Phosphorylation of MdmX by CDK2/ Cdc2(p34) is required for nuclear export of Mdm2. Oncogene 2005, 24: 2574-9.
32. Chen, L., Li, C., Pan, Y., Chen, J. Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol. Cell. Biol. 2005, 25: 6509-20.
33. Chen, L., Gilkes, D.M., Pan, Y., Lane, W.S., Chen, J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005, 4: 3411-22.
34. Pereg, Y., Lam, S., Teunisse, A., Biton, S., Meulmeester, E., Mittelman, L., Buscemi, G., Okamoto, K., Taya, Y., Shiloh, Y., Jochemsen, A.G. Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol. Cell. Biol. 2006, 26: 6819-31.
35. Pereg, Y., Shkedy, D., de Graaf, P., Meulmeester, E., Edelson-Averbukh, M., Salek, M., Biton, S., Teunisse, A.F., Lehmann, W.D., Jochemsen, A.G., Shiloh, Y. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. USA 2005, 102: 5056-61.
36. Jin, Y., Dai, M.S., Lu, S.Z., Xu, Y., Luo, Z., Zhao, Y., Lu, H. 14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J. 2006, 25: 1207-18.
37. Lopez-Pajares, V., Kim, M.M., Yuan, Z.M. Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. J. Biol. Chem. 2008, 283: 13707-13.
38. Okamoto, K., Kashima, K., Pereg, Y., Ishida, M., Yamazaki, S., Nota, A., Teunisse, A., Migliorini, D., Kitabayashi, I., Marine, J.C., Prives, C., Shiloh, Y., Jochemsen, A.G., Taya, Y. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell. Biol. 2005, 25: 9608-20.
39. Parant, J., Chavez-Reyes, A., Little, N.A., Yan, W., Reinke, V., Jochemsen, A.G., Lozano, G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 2001, 29: 92-5.
40. Migliorini, D., Lazzerini, Denchi, E., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P.G., Marine, J.C. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 2002, 22: 5527-38.
41. Finch, R.A., Donoviel, D.B., Potter, D., Shi, M., Fan, A., Freed, D.D., Wang, C.Y., Zambrowicz, B.P., Ramirez-Solis, R., Sands, A.T., Zhang, N. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 2002, 62: 3221-5.
42. Toledo, F., Wahl, G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6: 909-23.
43. Ongkeko, W.M., Wang, X.Q., Siu, W.Y., Lau, A.W., Yamashita, K., Harris, A.L., Cox, L.S., Poon, R.Y. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr. Biol. 1999, 9: 829-32.
44. Wang, X., Arooz, T., Siu, W.Y., Chiu, C.H., Lau, A., Yamashita, K., Poon, R.Y. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett. 2001, 490: 202-8.
45. Little, N.A., Jochemsen, A.G. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene 2001, 20: 4576-80.
46. Barboza, J.A., Iwakuma, T., Terzian, T., El-Naggar, A.K., Lozano, G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol. Cancer Res. 2008, 6: 947-54.
47. Strachan, G.D., Jordan-Sciutto, K.L., Rallapalli, R., Tuan, R.S., Hall, D.J. The E2F-1 transcription factor is negatively regulated by its interaction with the MDMX protein. J. Cell. Biochem. 2003, 88: 557-68.
48. Wunderlich, M., Ghosh, M., Weghorst, K., Berberich, S.J. MdmX represses E2F1 transactivation. Cell Cycle 2004, 3: 472-8.
49. Strachan, G.D., Rallapalli, R., Pucci, B., Lafond, T.P., Hall, D.J. A transcriptionally inactive E2F-1 targets the MDM family of proteins for proteolytic degradation. J. Biol. Chem. 2001, 276: 45677-85.
50. Meulmeester, E., Maurice, M.M., Boutell, C., Teunisse, A.F., Ovaa, H., Abraham, T.E., Dirks, R.W., Jochemsen, A.G. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 2005, 18: 565-76.
51. Meulmeester, E., Pereg, Y., Shiloh, Y., Jochemsen, A.G. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 2005, 4: 1166-70.
52. Li, C., Chen, L., Chen, J. DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms. Mol. Cell. Biol. 2002, 22: 7562-71.
53. Wang, X., Arooz, T., Siu,W.Y., Chiu, C.H., Lau, A., Yamashita, K., Poon, R.Y. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett. 2001, 490: 202-8.
54. Jackson, M.W., Lindstrom, M.S., Berberich, S.J. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J. Biol. Chem. 2001, 276: 25336-41.
55. Ghosh, M., Weghorst, K., Berberich, S.J. MdmX inhibits ARF mediated Mdm2 sumoylation. Cell Cycle 2005, 4: 604-8.
56. Jin, Y., Zeng, S.X., Sun, X.X., Lee, H., Blattner, C., Xiao, Z., Lu, H. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol. Cell. Biol. 2008, 28: 1218-29.
57. Kadakia, M., Brown, T.L., McGorry, M.M., Berberich, S.J. MdmX inhibits Smad transactivation. Oncogene 2002, 21: 8776-85.
58. Sabbatini, P., McCormick, F. MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol. 2002, 21: 519-25.
59. Uchida, C., Miwa, S., Isobe, T., Kitagawa, K., Hattori, T., Oda, T., Yasuda, H., Kitagawa, M. Effects of MdmX on Mdm2-mediated downregulation of pRB. FEBS Lett. 2006, 580: 1753-8.
60. Yam, C.H., Siu, W.Y., Arooz, T., Chiu, C.H., Lau, A., Wang, X.Q., Poon, R.Y. MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Cancer Res. 1999, 59: 5075-8.
61. Ramos, Y.F., Stad, R., Attema, J., Peltenburg, L.T., van der Eb, A.J., Jochemsen, A.G. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res. 2001, 1: 1839-42.
62. Rallapalli, R., Strachan, G., Cho, B., Mercer, W.E., Hall, D.J. A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J. Biol. Chem. 1999, 274: 8299-308.
63. Rallapalli, R., Strachan, G., Tuan, R.S., Hall, D.J. Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells. J. Cell. Biochem. 2003, 1: 563-75.
64. Bartel, F., Schulz, J., Böhnke, A., Blümke, K., Kappler, M., Bache, M., Schmidt, H., Würl, P., Taubert, H., Hauptmann, S. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int. J. Cancer 2005, 10: 469-75.
65. Prodosmo, A., Giglio, S., Moretti, S., Mancini, F., Barbi, F., Avenia, N., Di Conza, G., Schünemann, H.J., Pistola, L., Ludovini, V., Sacchi, A., Pontecorvi, A., Puxeddu, E., Moretti F. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J. Mol. Med. 2008, 86: 585-96.
66. Riemenschneider, M.J., Büschges, R., Wolter, M., Reifenberger, J., Boström, J., Kraus, J.A., Schlegel,U., Reifenberger, G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 1999, 59: 6091-6.
67. de Graaf, P., Little, N.A., Ramos, Y.F., Meulmeester, E., Letteboer, S.J., Jochemsen, A.G. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J. Biol. Chem. 2003, 3: 38315-24.
68. Giglio, S., Mancini, F., Gentiletti, F., Sparaco, G., Felicioni, L., Barassi, F., Martella, C., Prodosmo, A., Iacovelli, S., Buttitta, F., Farsetti, A., Soddu, S., Marchetti, A., Sacchi, A., Pontecorvi, A., Moretti, F. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res. 2005, 65: 9687-94.
69. Chandler, D.S., Singh, R.K., Caldwell, L.C., Bitler, J.L., Lozano, G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 2006, 66: 9502-8.
70. Shmueli, A., Oren, M. Mdm2: p53's lifesaver? Mol. Cell 2007, 25: 794-6.
71. Bartel, F., Taubert, H., Harris, L. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002, 2: 9-15.
72. Fridman, J.S., Hernando, E., Hemann, M.T., de Stanchina, E., Cordon-Cardo, C., Lowe, S.W., Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res. 2003, 63: 5703-6.
73. Steinman, H.A., Burstein, E., Lengner, C., Gosselin, J., Pihan, G., Duckett, C.S., Jones, S.N. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J. Biol. Chem. 2004, 279: 4877-86.